Brand Name :
Anaprox, Naprosyn, Naproxen EC, Aleve, EC Naprosyn, naprox sodium
Synonyms :
Naprolag, naproxen, naproxeno
Class :
Non-steroidal anti-inflammatory drugs
Brand Name :
Anaprox, Naprosyn, Naproxen EC, Aleve, EC Naprosyn, naprox sodium
Synonyms :
Naprolag, naproxen, naproxeno
Class :
Non-steroidal anti-inflammatory drugs
Dosage Forms & Strengths
Tablet
220mg
250mg
275mg
375mg
500mg
550mg
Delayed release tablets
375mg
500mg
Extended-release tablets
375mg
500mg
750mg
Oral suspension
25mg/ml
Capsule
220mg
Dosage Forms & Strengths
Tablet
220mg
250mg
275mg
375mg
500mg
550mg
Delayed release tablets
375mg
500mg
Extended-release tablets
375mg
500mg
750mg
Oral suspension
25mg/ml
Capsule
220mg
Refer adult dosing
it may enhance the adverse/toxic effect of apixaban
antacids decrease the systemic absorption of naproxen
antacids decrease the systemic absorption of naproxen
antacids decrease the systemic absorption of naproxen
antacids decrease the systemic absorption of naproxen
antacids decrease the systemic absorption of naproxen
they decrease the absorption of naproxen
they decrease the absorption of naproxen
they decrease the absorption of naproxen
they decrease the absorption of naproxen
they decrease the absorption of naproxen
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
it increases the toxicity of naproxen
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may diminish the absorption of non-steroidal anti-inflammatory drugs
may increase the anti-platelet effect of anti-coagulants agents
may increase the anti-platelet effect of anti-coagulants agents
may increase the anti-platelet effect of anti-coagulants agents
may increase the anti-platelet effect of anti-coagulants agents
may increase the anti-platelet effect of anti-coagulants agents
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may decrease the excretion of non-steroidal anti-inflammatory drugs
may decrease the excretion of non-steroidal anti-inflammatory drugs
may decrease the excretion of non-steroidal anti-inflammatory drugs
may decrease the excretion of non-steroidal anti-inflammatory drugs
may decrease the excretion of non-steroidal anti-inflammatory drugs
may increase the nephrotoxic effect of non-steroidal anti-inflammatory drugs
may increase the nephrotoxic effect of non-steroidal anti-inflammatory drugs
anticoagulation is increased by dalteparin and decreased by mistletoe. The interaction's effect is unclear; exercise caution
Mechanism of action
It is a non-steroidal anti-inflammatory drug (NSAID) that works by blocking the production of prostaglandins, chemicals in the body that cause inflammation and pain. Its action inhibits cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By inhibiting these enzymes, naproxen reduces the production of prostaglandins and thus reduces inflammation and pain
Spectrum
The spectrum of naproxen activity includes treating pain, inflammation, and fever. It is commonly used to treat rheumatoid arthritis, osteoarthritis, gout, and menstrual cramps. It can also alleviate pain caused by injuries, such as sprains and strains, and reduce fever
Frequency defined:
1-10%
Constipation
Drowsiness
Heart burn
Edema
GI perforation
GI ulcers
Diarrhea
Diverticulitis
Hearing disturbances
Abdominal pain
Dizziness
Headache
Nausea
GI bleeding
Lightheadedness
Fluid retention
Stomatitis
Dyspnea
Black box warning
It is a non-steroidal anti-inflammatory drug (NSAID), carries a black box warning for an increased heart attack or stroke risk. This warning is the most severe from the U.S. Food and Drug Administration (FDA) and indicates that the drug may cause severe or life-threatening side effects.
Patients taking naproxen should talk to their healthcare provider about the potential risks and benefits of the medication and follow the recommended dosage and duration of use.
Contraindications
Caution
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology
It is a non-steroidal anti-inflammatory drug (NSAID) that inhibits the synthesis of prostaglandins in body tissues. Prostaglandins are chemicals that play a crucial role in inflammation, pain, and fever. Naproxen is an NSAID that works by inhibiting the activity of two enzymes, COX-1 and COX-2, which are responsible for the production of prostaglandins. By inhibiting the activity of these enzymes, Naproxen reduces the synthesis of prostaglandins and thereby reduces inflammation, pain, and fever. Naproxen may also have anti-inflammatory effects by inhibiting chemotaxis, altering lymphocyte activity, decreasing pro-inflammatory cytokine activity, and inhibiting neutrophil aggregation.
Pharmacodynamics
Inhibition of prostaglandin synthesis: It is a non-selective COX inhibitor, which inhibits the activity of both COX-1 and COX-2 enzymes. These enzymes are responsible for the production of prostaglandins, which play a crucial role in inflammation, pain, and fever. By inhibiting the activity of these enzymes, Naproxen reduces the synthesis of prostaglandins and thereby reduces inflammation, pain, and fever.
Anti-inflammatory effects: It has anti-inflammatory effects by inhibiting the activity of several mediators of inflammation, such as leukotrienes, and by reducing the production of pro-inflammatory cytokines.
Analgesic effects: It acts as an analgesic by reducing the synthesis of prostaglandins, which are involved in transmitting pain signals in the body.
Antipyretic effects: It has antipyretic effects by reducing the production of prostaglandins, which regulate body temperature.
Platelet inhibition: It has a weak anti-platelet effect by inhibiting the production of thromboxane A2, a prostaglandin involved in platelet aggregation.
Pharmacokinetics
Absorption
The absorption of the medication is 95% bioavailable, with an onset of 30-60 minutes and a duration of fewer than 12 hours. The peak serum time for tablets is 1-4 hours; for delayed release on an empty stomach, it is 2-12 hours, and for delayed release with food, it is 4-24 hours. The peak plasma concentration is 62-96 mcg/mL
Distribution
The drug is mostly protein bound at less than 99%. The volume of distribution is 0.16 L/kg.
Metabolism
It is metabolized in the liver via conjugation, with 6-Desmethylnaproxen and glucuronide conjugates as metabolites. The enzymes COX-1 and COX-2 are inhibited.
Elimination/excretion
The half-life is 12-17 hours and is not dialyzable. The clearance of the medication is 0.13 mL/min/kg, and it is excreted mainly in the urine (95%) and, to a lesser extent, in the feces (<3%)
Administration
It is typically administered orally in the form of tablets or capsules. The recommended dosage will vary depending on the treated condition and the individual’s response to the medication. It is usually taken every 8-12 hours with food to reduce the risk of stomach upset.
Patient information leaflet
Generic Name: naproxen
Pronounced: [ na-PROX-en ]
Why do we use naproxen?
It is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain, reduce inflammation, and lower fever. It is used to treat a wide range of conditions, including: